The early diagnosis of Alzheimer's disease: Blood‐based panel biomarker discovery by proteomics and metabolomics
CNS Neuroscience & Therapeutics · 2024-11 · 30 (11)
DOI: 10.1111/cns.70060 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 21.11.2024. Verfasst von Yun Dong und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Shenzhen Technology University, Shenzhen, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Early Diagnosis, Metabolomics. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Major Projects of Guangdong Education Department for Foundation Research and Applied Research, Shenzhen Municipal Science and Technology Innovation Council, the Innovation Team Project of Gongdong Provincial Department of Education.
Themen: Demenz
Abstract (Originalsprache)
Diagnosis and prediction of Alzheimer's disease (AD) are increasingly pressing in the early stage of the disease because the biomarker‐targeted therapies may be most effective. Diagnosis of AD largely depends on the clinical symptoms of AD. Currently, cerebrospinal fluid biomarkers and neuroimaging techniques are considered for clinical detection and diagnosis. However, these clinical diagnosis results could provide indications of the middle and/or late stages of AD rather than the early stage, and another limitation is the complexity attached to limited access, cost, and perceived invasiveness. Therefore, the prediction of AD still poses immense challenges, and the development of novel biomarkers is needed for early diagnosis and urgent intervention before the onset of obvious phenotypes of AD. Blood‐based biomarkers may enable earlier diagnose and aid detection and prognosis for AD because various substances in the blood are vulnerable to AD pathophysiology. The application of a systematic biological paradigm based on high‐throughput techniques has demonstrated accurate alterations of molecular levels during AD onset processes, such as protein levels and metabolite levels, which may facilitate the identification of AD at an early stage. Notably, proteomics and metabolomics have been used to identify candidate biomarkers in blood for AD diagnosis. This review summarizes data on potential blood‐based biomarkers identified by proteomics and metabolomics that are closest to clinical implementation and discusses the current challenges and the future work of blood‐based candidates to achieve the aim of early screening for AD. We also provide an overview of early diagnosis, drug target discovery and even promising therapeutic approaches for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Shenzhen Technology University, Shenzhen, China.
- Department of Pharmacy, Shenzhen People's Hospital (The Second Clinical Medical College, The First Affiliated Hospital, Jinan University, Southern University of Science and Technology), Shenzhen, China.
- School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, China.
ORCID-Profile: Yun Dong
Förderung
- Major Projects of Guangdong Education Department for Foundation Research and Applied Research
- Shenzhen Municipal Science and Technology Innovation Council
- the Innovation Team Project of Gongdong Provincial Department of Education
Zitieren
APA
Dong, Y., Song, X., Wang, X., Wang, S., & He, Z. (2024). The early diagnosis of Alzheimer's disease: Blood‐based panel biomarker discovery by proteomics and metabolomics. CNS Neuroscience & Therapeutics, 30(11). https://doi.org/10.1111/cns.70060
Vancouver
Dong Y, Song X, Wang X, Wang S, He Z. The early diagnosis of Alzheimer's disease: Blood‐based panel biomarker discovery by proteomics and metabolomics. CNS Neuroscience & Therapeutics. 2024;30(11). doi:10.1111/cns.70060
BibTeX
@article{Dong2024,
author = {Dong, Yun and Song, Xun and Wang, Xiao and Wang, Shaoxiang and He, Zhendan},
title = {The early diagnosis of Alzheimer's disease: Blood‐based panel biomarker discovery by proteomics and metabolomics},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
volume = {30},
number = {11},
doi = {10.1111/cns.70060}
}
EUVIMED